According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105.HK) announced that the group has initiated the enrollment of participants in the LAE102 Phase I multi-dose expansion study for the treatment of obesity in China, and has completed the administration of the first subject.

Zhitongcaijing · 3d ago
According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105.HK) announced that the group has initiated the enrollment of participants in the LAE102 Phase I multi-dose expansion study for the treatment of obesity in China, and has completed the administration of the first subject.